Evidence map›Paper›PMID 38883315›Full record

ArticleBioactive materials2024

Turning foes to friends: Advanced "

Ze Wang, Tong Sha, Jinwei Li, Huanyu Luo, Annan Liu, Hao Liang, Jinbiao Qiang, Lei Li, Andrew K Whittaker, Bai Yang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ze WangState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, PR China.
Tong ShaDepartment of Oral Pathology, Hospital of Stomatology, Jilin University, Changchun, 130021, PR China.
Jinwei LiDepartment of Oral Pathology, Hospital of Stomatology, Jilin University, Changchun, 130021, PR China.
Huanyu LuoDepartment of Oral Pathology, Hospital of Stomatology, Jilin University, Changchun, 130021, PR China.
Annan LiuState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, PR China.
Hao LiangState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, PR China.
Jinbiao QiangDepartment of Oral Pathology, Hospital of Stomatology, Jilin University, Changchun, 130021, PR China.
Lei LiDepartment of Endocrinology, Lequn Branch, The First Hospital of Jilin University, 130021, PR China.
Andrew K WhittakerAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
Bai YangState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, PR China.
Hongchen SunDepartment of Oral Pathology, Hospital of Stomatology, Jilin University, Changchun, 130021, PR China.
Ce ShiDepartment of Oral Pathology, Hospital of Stomatology, Jilin University, Changchun, 130021, PR China.
Quan LinState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a "cold tumor", triple-negative breast cancer (TNBC) exhibits limited responsiveness to current immunotherapy. How to enhance the immunogenicity and reverse the immunosuppressive microenvironment of TNBC remain a formidable challenge. Herein, an "

Indexed as

Dual immunoregulationImmunogenic cell deathIn situ nanovaccineMetastatic triple-negative breast cancerSynergistic therapy

Identifiers

PMID38883315
PMCPMC11179173

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.